|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C12N 5/0636 | (2013.01) |
| A61K 39/00 | (2006.01) | ||
| C12N 5/0783 | (2010.01) | ||
| C12N2510/00 | (2013.01) | ||
| A61K 35/17 | (2015.01) | ||
| C12N2310/20 | (2017.05) | ||
| A61K 38/00 | (2006.01) | ||
| C12N 15/1138 | (2013.01) | ||
| C12N 15/113 | (2010.01) | ||
| C12N2310/315 | (2013.01) | ||
| C12N 15/90 | (2006.01) | ||
| A61K 38/00 | (2013.01) | ||
| A61K 48/00 | (2006.01) | ||
| C12N 15/907 | (2013.01) | ||
| C12N2750/14143 | (2013.01) | ||
| A61K 48/00 | (2013.01) | ||
| A61K 39/4611 | (2023.05) | ||
| A61K 39/4631 | (2023.05) | ||
| A61K 39/464438 | (2023.05) | ||
| A61K 39/464417 | (2023.05) | ||
| A61K 39/464412 | (2023.05) | ||
| A61K2239/26 | (2023.05) | ||
| A61K2239/48 | (2023.05) | ||
| A61K2239/38 | (2023.05) | ||
| A61K2239/54 | (2023.05) | ||
| A61K2239/56 | (2023.05) | ||
| A61K2239/31 | (2023.05) | ||
| A61K 39/464462 | (2023.05) |
| (11) | Number of the document | 4176048 |
| (13) | Kind of document | T |
| (96) | European patent application number | 21787042.7 |
| Date of filing the European patent application | 2021-09-23 | |
| (97) | Date of publication of the European application | 2023-05-10 |
| (45) | Date of publication and mention of the grant of the patent | 2024-09-11 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/IB2021/058704 |
| Date | 2021-09-23 |
| (87) | Number | WO 2022/064428 |
| Date | 2022-03-31 |
| (30) | Number | Date | Country code |
| 202063082357 P | 2020-09-23 | US | |
| 202063124429 P | 2020-12-11 | US | |
| 202163225673 P | 2021-07-26 | US |
| (72) |
DEQUEANT, Mary-Lee , US
KALAITZIDIS, Demetrios , US
GHONIME, Mohammed , US
|
| (73) |
CRISPR Therapeutics AG ,
Baarerstrasse 14, 6300 Zug,
CH
|
| (54) | GENETICALLY ENGINEERED T CELLS WITH REGNASE-1 AND/OR TGFBRII DISRUPTION HAVE IMPROVED FUNCTIONALITY AND PERSISTENCE |
| GENETICALLY ENGINEERED T CELLS WITH REGNASE-1 AND/OR TGFBRII DISRUPTION HAVE IMPROVED FUNCTIONALITY AND PERSISTENCE |